13 Apr 2026
13m
Spyre Therapeutics announced today that SPY001, an extended half-life α4β7, showed a 40% clinical remission rate at 12 weeks in moderate-to-severe UC
BiotechTV - News
Open in Podwise to generate AI notes
Sign in to process this episode and unlock summaries, transcripts, highlights and translations.
Shownotes are not generated by Podwise.